Articles related to CLINICAL TRIALS

The omission or problematic use of crossover in oncology clinical trials raises significant ethical and interpretive questions; delve into the details and implications for your practice today.

This Phase 1-2 study presents compelling evidence for the efficacy of mezigdomide in combination with dexamethasone for patients with relapsed and refractory multiple myeloma. Explore the study to understand how this novel treatment could eventually fit into your therapeutic strategy.

This pooled analysis provides robust evidence that low-dose glucocorticoids in RA treatment result in modest weight gain but do not elevate blood pressure. Consider these findings in your risk-benefit discussions with patients.

The FDA’s recent decision allows Fulcrum Therapeutics to continue its Phase 1b trial of FTX-6058, an oral therapy for SCD. The trial aims to explore the drug’s potential in increasing fetal hemoglobin levels, offering a new avenue for treatment.

Explore the phase 1 study findings on Divarasib, a covalent KRAS G12C inhibitor, which has shown durable clinical responses with a favorable safety profile in patients with KRAS G12C-positive tumors.

The recent phase 3 trial of vorasidenib in patients with grade 2 IDH-mutant glioma has demonstrated significant improvements in progression-free survival and time to next intervention. Explore the detailed findings to understand how this oral inhibitor could become a vital part of the treatment regimen for this challenging condition.